On November 12, 2025, Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of Lupin Limited, announced the commissioning of a dedicated Oncology Block at its Vizag facility in India.
This cutting-edge expansion marks a major step in strengthening LMS’s global contract development and manufacturing organisation (CDMO) capabilities for high-potency oncology APIs.
The newly inaugurated Oncology Block spans 4,270 square metres and features 20 reactors ranging from 250L to 2,000L, equipped with more than 20 isolators. The unit ensures ultra-low exposure levels of ≤0.05 μg/m³, providing high containment and safety. Designed for flexible production scale-ups between 1–35 kg batches, it maintains optimal environmental controls at ≤25°C temperature and ≤45% relative humidity.
This facility positions LMS as a premier partner for oncology innovators across the preclinical to commercial stages of development.
The Vizag Oncology Block integrates a Process Development Laboratory with a dedicated Quality Control Laboratory, enabling seamless transition from early-stage research to full-scale manufacturing. With advanced SCADA systems, isolator-based operations, and an efficient effluent detoxification system, the facility complies with stringent international regulatory and environmental standards. This end-to-end approach ensures faster, safer, and compliant production of oncology APIs that meet global quality benchmarks.
Read More: Lupin Q2 Results | EBITDA Grows 74.7% YoY to ₹2,341.7 Crore, Revenue Sees Strong Growth!
According to Dr. Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions, the inauguration of this state-of-the-art facility underscores Lupin’s commitment to advancing oncology research and manufacturing excellence. The Oncology Block enhances the company’s ability to deliver impactful, high-quality APIs that enable faster delivery of cancer therapies to patients worldwide. Supported by a team of 250+ scientists with specialised HPAPI expertise, LMS aims to accelerate the development of life-changing oncology treatments.
Lupin Manufacturing Solutions Limited is a 100% subsidiary of Lupin Limited, specialising in active pharmaceutical ingredients, complex chemistry, and advanced modalities such as antibody-drug conjugates (ADCs) and peptides. Leveraging Lupin’s scientific legacy and regulatory strength, LMS offers integrated drug substance and product development solutions for biopharma innovators, ensuring faster and more efficient paths to market.
On November 12, 2025, Lupin share price opened at ₹1,983.20 on NSE, above the previous close of ₹1,975.90. During the day, it surged to ₹2,018.40 and dipped to ₹1,971.80. The stock is trading at ₹2,017.40 as of 1:06 PM. The stock registered a significant gain of 2.10%.
Over the past week, it has moved up by 3.17%, over the past month, it has moved up by 4.13%, and over the past 3 months, it has moved up by 3.79%.
With the commissioning of its dedicated Oncology Block in Vizag, Lupin Manufacturing Solutions has reinforced its position as a trusted global CDMO partner. This facility strengthens its capabilities in oncology drug manufacturing, combining containment excellence, scientific precision, and regulatory compliance to support global innovators in bringing cancer therapies to market more efficiently.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Nov 12, 2025, 1:58 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN